Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review. (Q38006975)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Zdravko Jotanovic

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Radovan Mihelic

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Branko Sestan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

343-358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22550965%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11599350-000000000-00000

30 January 2020

exact match

0 references

cites work

New thoughts on the pathophysiology of osteoarthritis: one more step toward new therapeutic targets

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Osteoarthritis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Genetics of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Anticytokine therapy for osteoarthritis: evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Role of proinflammatory cytokines in the pathophysiology of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Erosive osteoarthritis of the hand: clinical experience with anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Rilonacept in the treatment of chronic inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Interleukin-1 receptor antagonist

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

21 January 2018

12 December 2020

The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Rhein, an active metabolite of diacerein, suppresses the interleukin-1alpha-induced proteoglycan degradation in cultured rabbit articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Effects of rhein on human articular chondrocytes in alginate beads

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Medico-economic analysis of diacerein with or without standard therapy in the treatment of osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Effectiveness of nonpharmacological and nonsurgical interventions for hip osteoarthritis: an umbrella review of high-quality systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Purification of interleukin-1 beta converting enzyme, the protease that cleaves the interleukin-1 beta precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Matrix metalloproteinases: role in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Gene transfer to synoviocytes: prospects for gene treatment of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Anticytokine therapy for osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Getting arthritis gene therapy into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599350-000000000-00000

Effect of diacetylrhein on the phagocytosis of polymorphonuclear leucocytes and its influence on the biosynthesis of hyaluronate in synovial cells

21 January 2018

1 reference

12 December 2020

The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis

1 reference

12 December 2020

Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis

1 reference

12 December 2020

Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group

1 reference

12 December 2020

Diacerhein in the treatment of osteoarthritis of the hip

1 reference

12 December 2020

The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study

1 reference

12 December 2020

Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression

1 reference

12 December 2020

Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes

1 reference

12 December 2020

Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor

1 reference

12 December 2020

The interleukin-1 receptor antagonist and its delivery by gene transfer.

1 reference

12 December 2020

Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production

1 reference

12 December 2020

Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta

1 reference

12 December 2020

Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures

1 reference

12 December 2020

Biologic basis for interleukin-1 in disease

1 reference

12 December 2020

Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I

1 reference

12 December 2020

Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function

1 reference

12 December 2020

Phenyl N-tert-butylnitrone down-regulates interleukin-1 beta-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1

1 reference

12 December 2020

Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients

1 reference

12 December 2020

Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes

1 reference

12 December 2020

[Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis]

1 reference

12 December 2020

Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels

1 reference

12 December 2020

Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1beta and interleukin-18

1 reference

12 December 2020

A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis

1 reference

12 December 2020

Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study

1 reference

12 December 2020

IL-1 trap. Regeneron/Novartis.

1 reference

12 December 2020

Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention

1 reference

12 December 2020

Diacerein for osteoarthritis

1 reference

12 December 2020

Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for Diacerein effects in osteoarthritis

1 reference

12 December 2020

In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes

1 reference

12 December 2020

Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage

1 reference

12 December 2020